Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA was submitted on December 12, 2017, covering a notification dated December 8, 2017. The filing announces the implementation of a share buy-back programme pursuant to an authorization granted by the General Meeting on May 12, 2016.
Key Financial Metrics
The filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data provided relates to the capital allocation for the share repurchase:
- Maximum Repurchase Value: Up to 61 million Euro (approximately 72 million U.S. Dollar).
- Share Quantity: Up to 660,000 ordinary shares (ISIN DE0005785802).
- Capital Impact: Represents approximately 0.21% of the Company's share capital.
- Execution Period: December 11, 2017, through December 22, 2017.
Material Changes
The filing does not disclose material changes to the Company's business operations, financial position, or results of operations compared to prior periods. The primary change is the initiation of a specific capital reduction activity.
Guidance, Outlook, and Management Commentary
Purpose of Buy-back: The repurchased shares will be cancelled to reduce registered share capital. This action is specifically intended to neutralize dilution resulting from the Stock Option Plan 2011.
Execution Constraints:
- Shares will be repurchased via the XETRA trading system.
- Price limits: The purchase price must not deviate by more than 10% from the opening auction market price on the trading day.
- Volume limits: Purchases are capped at 25% of the average daily volume (based on the preceding 20 trading days).
- Independence: A credit institution will execute the programme independently of Company influence.
Disclosure: Transaction details will be published on the Company's website within seven trading days of execution.
Investor Verification Checklist
- Verify the actual volume and average price of shares repurchased during the December 11–22, 2017 window via the Company's investor relations website.
- Confirm the final reduction in registered share capital following the cancellation of repurchased shares.
- Review the impact of this buy-back on the dilution metrics of the Stock Option Plan 2011.
- Note that this filing contains no updated guidance on revenue, earnings, or cash flow for the fiscal year.